Ko-Med Centra Kliniczne Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Ko‑Med Centra Kliniczne site conducts research aimed at reducing heart‑related events and improving blood‑vessel health in adults at elevated risk.
- Evaluating the novel anticoagulant asundexian for stroke and systemic embolism prevention in atrial fibrillation
- Assessing the impact of the lipid‑lowering antibody evolocumab on coronary death, myocardial infarction and ischemic stroke
- Long‑term safety and efficacy study of the APOC3 inhibitor ARO‑APOC3 in mixed dyslipidemia
- Risk‑reduction strategies for patients with high cardiovascular risk but no prior myocardial infarction or stroke
With five active trials and a team of 24 investigators, the Pulawy centre is a hub for advancing cardiovascular therapeutics across Europe.
Nutritional and Metabolic Diseases
Research at this facility focuses on metabolic imbalances, particularly abnormalities in blood lipids that increase cardiovascular danger.
- Investigation of APOC3 inhibition using ARO‑APOC3 to improve lipid profiles in adults with mixed dyslipidemia
- Evaluation of optimized lipid‑lowering regimens combined with novel agents for high‑risk patients
- Studies on metabolic risk factors that contribute to atherosclerotic disease
- Assessment of safety and long‑term outcomes of metabolic therapies in a real‑world population
The centre’s multidisciplinary team applies its expertise to develop better treatments for metabolic disorders, supporting both patients and clinicians.
Skin and Connective Tissue Diseases
This site is engaged in advancing care for inflammatory skin conditions, with a particular emphasis on moderate psoriasis.
- Dose‑selection study of the oral agent HRO350 for mild‑to‑moderate psoriasis
- Safety monitoring of new systemic therapies in adult patients with skin disease
- Comparative effectiveness research to identify optimal treatment regimens for psoriasis
- Exploration of patient‑reported outcomes to improve quality of life in dermatologic care
By integrating clinical evaluation with patient feedback, the Pulawy centre contributes to more personalized dermatology solutions.
Virus Diseases
The clinic investigates vaccine strategies to protect older adults from respiratory viral infections and related bacterial complications.
- Immune‑response assessment of the RSV investigational vaccine RSVPreF3 OA in seniors
- Co‑administration study of RSVPreF3 OA with the 20‑valent pneumococcal conjugate vaccine PCV20
- Safety and reactogenicity monitoring of combined viral‑bacterial vaccination in adults aged 60+
- Evaluation of neutralizing antibody levels against RSV‑A and RSV‑B subtypes
These vaccine trials aim to enhance protection against respiratory syncytial virus and pneumococcal disease, reflecting the site’s commitment to public‑health‑focused research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ko-Med Centra Kliniczne Sp. z o.o.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of HRO350 in subjects with mild-to-moderate psoriasis (the ‘HeROPA’ study) | Arctic Bioscience AS | Phase II | Not Recruiting | Mar 2023 | Mar 2025 |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 1 | Unknown | 2022-11-24 | 2022-11-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.